Alejandro González Veliz: How Plaque Morphology Shapes PCI Outcomes
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn:
”Same stent. Different plaque. Different outcome.
Does plaque morphology matter after PCI?
A new substudy of ILUMIEN IV evaluated preprocedural OCT-defined plaque morphology and its association with procedural and clinical outcomes after PCI.
Among 926 patients with a single de novo lesion, plaques were classified as predominantly lipidic, calcific, or fibrotic based on OCT.
The findings were striking:
- Calcific plaques had the lowest stent expansion and the highest 2-year target-vessel failure (TVF).
- Fibrotic plaques had the lowest clinical event rate.
- Lipidic plaques achieved the greatest acute luminal gain, but their 2-year clinical risk was intermediate.
At 2 years, TVF occurred in:
10.7 percent — Calcific
5.6 percent — Lipidic
4.0 percent — Fibrotic
For calcific vs fibrotic lesions, the adjusted HR for TVF was 2.20 (95 percent CI 1.12–4.33; P equals zero point zero twoՃ, driven primarily by increased ischemia-driven target-vessel revascularization.
The message is not that plaque morphology alone determines outcome.
Rather, OCT may provide information about lesion biology and mechanical behavior that angiography cannot fully capture—information that can influence lesion preparation, stent deployment, expansion, and optimization.
One important caveat: this was a secondary analysis of the OCT-guided arm of ILUMIEN IV, so these findings demonstrate an association rather than proving that plaque phenotype itself causes worse outcomes.
Know the plaque.
Optimize the PCI.”

Stay updated with Hemostasis Today.
-
Oct 12, 2026, 17:39Annie Bauzon: Differentiating Direct and Indirect Coombs Tests in Hematology
-
Oct 12, 2026, 17:15Cedric Hermans: Identifying and Diagnosing Hemophilia Carriers and Affected Females
-
Oct 12, 2026, 17:01Bianca Rocca: Evaluating Factor XI Inhibition Lessons from LIBREXIA-ACS
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026